AR061604A1 - SYNTHESIS OF AN INSULINOTROPIC PEPTIDE - Google Patents
SYNTHESIS OF AN INSULINOTROPIC PEPTIDEInfo
- Publication number
- AR061604A1 AR061604A1 ARP070102735A ARP070102735A AR061604A1 AR 061604 A1 AR061604 A1 AR 061604A1 AR P070102735 A ARP070102735 A AR P070102735A AR P070102735 A ARP070102735 A AR P070102735A AR 061604 A1 AR061604 A1 AR 061604A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- fragment
- optionally include
- sequence
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente solicitud está relacionada con la preparacion de péptidos insulinotropicos que se sintetizan utilizando un método en fase solida y en solucion ('hibridaö). En general, el método incluye la síntesis de tres fragmentos de péptido intermediarios diferentes utilizando la química de fase solida. Entonces se utiliza la química de fase en solucion para anadir material de aminoácidos adicional a uno de los fragmentos. Entonces se acoplan los fragmentos en la fase en solucion solida. La utilizacion de una pseudoprolina en uno de los fragmentos facilita la síntesis en fase solida de ese fragmento y también facilita el subsiguiente acoplamiento en fase en solucion de este fragmento con otros fragmentos. La presente solicitud es muy util para la formacion de péptidos insulinotropicos como el GLP-1(7-36) y sus homologos naturales y no naturales. Reivindicacion 1: Un método para obtener un péptido insulinotropico, que comprende uno o más de los siguientes pasos: h) proporcionar un primer fragmento peptídico que incluye la secuencia de aminoácidos HX8EX10 (Id. de Sec. N° 6), en la que X8 y X10 son ambos residuos de un aminoácido aquiral, tanto H como E incluyen opcionalmente la proteccion de la cadena lateral; i) proporcionar un segundo fragmento peptídico que incluye la secuencia de aminoácidos TFTSDVX17-18YLEG (Id. de Sec. N° 8) en la que el residuo denotado mediante el símbolo X17-18 es un residuo dipeptídico de pseudoprolina, y dichos residuos de aminoácidos de la secuencia incluyen opcionalmente la proteccion de la cadena lateral; j) acoplar el primer fragmento al segundo fragmento para proporcionar un tercer fragmento peptídico que incluye la secuencia de aminoácidos HX8EX10TFTSDVX17-18YLEG (Id. de Sec. N° 11), y dichos residuos de aminoácidos de la secuencia incluyen opcionalmente la proteccion de la cadena lateral; k) proporcionar un cuarto fragmento peptídico que incluye la secuencia de aminoácidos QAAKEFIAWLVKX35 (Id. de Sec. N° 9), en el que X35 es un residuo de un aminoácido aquiral y dichos residuos de aminoácidos de la secuencia incluyen opcionalmente la proteccion de la cadena lateral; l) acoplar el cuarto fragmento peptídico a arginina para proporcionar un quinto fragmento peptídico que incluye la secuencia de aminoácidos QAAKEFIAWLVKX35R (Id. de Sec. N° 12), y dichos residuos de la secuencia incluyen opcionalmente la proteccion de la cadena lateral; y m) acoplar el quinto fragmento al tercer fragmento para proporcionar un péptido insulinotropico que incluye la secuencia de aminoácidos HX8EX10TFTSDVX17-18YLEGQAAkEFIAWLVK X35R (Id. de Sec. N° 13), y dichos residuos de la secuencia incluyen opcionalmente la proteccion de la cadena lateral. Reivindicacion 8: Un fragmento peptídico con la secuencia de aminoácidos HX8EX10 (Id. de Sec. N° 6), en el que X8 y X10 son ambos residuos de un aminoácido aquiral, tanto H como E, X8 y X10 incluyen opcionalmente la proteccion de la cadena lateral.The present application is related to the preparation of insulinotropic peptides that are synthesized using a solid phase and solution method ('hibridaö). In general, the method includes the synthesis of three different intermediate peptide fragments using solid phase chemistry. Then the phase chemistry in solution is used to add additional amino acid material to one of the fragments. The fragments are then coupled in the solid solution phase. The use of a pseudoproline in one of the fragments facilitates the solid phase synthesis of that fragment and also facilitates the subsequent phase coupling in solution of this fragment with other fragments. The present application is very useful for the formation of insulinotropic peptides such as GLP-1 (7-36) and their natural and unnatural counterparts. Claim 1: A method of obtaining an insulinotropic peptide, comprising one or more of the following steps: h) providing a first peptide fragment that includes the amino acid sequence HX8EX10 (Seq. ID No. 6), wherein X8 and X10 are both residues of an aquiral amino acid, both H and E optionally include side chain protection; i) providing a second peptide fragment that includes the amino acid sequence TFTSDVX17-18YLEG (Seq. ID No. 8) in which the residue denoted by the symbol X17-18 is a dipeptide residue of pseudoproline, and said amino acid residues of the sequence optionally include side chain protection; j) coupling the first fragment to the second fragment to provide a third peptide fragment that includes the amino acid sequence HX8EX10TFTSDVX17-18YLEG (Seq. ID No. 11), and said amino acid residues of the sequence optionally include chain protection side; k) providing a fourth peptide fragment that includes the amino acid sequence QAAKEFIAWLVKX35 (Sec. No. 9), wherein X35 is a residue of an aquiral amino acid and said amino acid residues of the sequence optionally include the protection of the side chain; l) coupling the fourth peptide fragment to arginine to provide a fifth peptide fragment that includes the amino acid sequence QAAKEFIAWLVKX35R (Seq. ID No. 12), and said sequence residues optionally include side chain protection; and m) coupling the fifth fragment to the third fragment to provide an insulinotropic peptide that includes the amino acid sequence HX8EX10TFTSDVX17-18YLEGQAAkEFIAWLVK X35R (Seq. ID No. 13), and said sequence residues optionally include side chain protection. Claim 8: A peptide fragment with the amino acid sequence HX8EX10 (Seq. ID No. 6), wherein X8 and X10 are both residues of an aquiral amino acid, both H and E, X8 and X10 optionally include the protection of the side chain
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81591906P | 2006-06-23 | 2006-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR061604A1 true AR061604A1 (en) | 2008-09-10 |
Family
ID=38596729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070102735A AR061604A1 (en) | 2006-06-23 | 2007-06-21 | SYNTHESIS OF AN INSULINOTROPIC PEPTIDE |
Country Status (33)
Country | Link |
---|---|
US (2) | US20080004429A1 (en) |
EP (1) | EP2035451B1 (en) |
JP (1) | JP4537495B2 (en) |
KR (1) | KR101087859B1 (en) |
CN (1) | CN101563364B (en) |
AR (1) | AR061604A1 (en) |
AT (1) | ATE466881T1 (en) |
AU (1) | AU2007263043B2 (en) |
BR (1) | BRPI0713575A2 (en) |
CA (1) | CA2654610C (en) |
CL (1) | CL2007001835A1 (en) |
CR (1) | CR10463A (en) |
CY (1) | CY1110186T1 (en) |
DE (1) | DE602007006310D1 (en) |
DK (1) | DK2035451T3 (en) |
EC (1) | ECSP088999A (en) |
ES (1) | ES2341588T3 (en) |
HR (1) | HRP20100302T1 (en) |
IL (1) | IL195421A0 (en) |
MA (1) | MA30530B1 (en) |
MX (1) | MX2008015935A (en) |
MY (1) | MY144608A (en) |
NO (1) | NO20084863L (en) |
NZ (1) | NZ573093A (en) |
PL (1) | PL2035451T3 (en) |
PT (1) | PT2035451E (en) |
RS (1) | RS51281B (en) |
RU (1) | RU2448978C2 (en) |
SI (1) | SI2035451T1 (en) |
TW (1) | TWI331155B (en) |
UA (1) | UA96602C2 (en) |
WO (1) | WO2007147816A1 (en) |
ZA (1) | ZA200810072B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5473925B2 (en) | 2007-10-27 | 2014-04-16 | コーデン ファーマ コロラド インコーポレイテッド | Synthesis of insulinotropic peptides using combined solid-phase and solution-phase techniques |
CN101903400B (en) * | 2007-12-11 | 2013-12-18 | 霍夫曼-拉罗奇有限公司 | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
US20100317057A1 (en) * | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
US20100183876A1 (en) * | 2008-12-23 | 2010-07-22 | Hell Andre | Process for the Preparation of a Peptide Powder Form |
WO2010125079A2 (en) * | 2009-05-01 | 2010-11-04 | F. Hoffmann-La Roche Ag | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
US20110313131A1 (en) * | 2010-06-21 | 2011-12-22 | Christelle Carl | Reversed phase hplc purification of a glp-1 analogue |
US20120157382A1 (en) | 2010-12-21 | 2012-06-21 | Siegfried Krimmer | Pharmaceutical glp-1 compositions having an improved release profile |
DK2788110T3 (en) * | 2011-12-08 | 2019-02-11 | Pentair Water Pool & Spa Inc | AQUACULTURE SYSTEM AND PROCEDURE TO OPERATE A PUMP IN SUCH A SYSTEM |
ES2682253T3 (en) | 2011-12-29 | 2018-09-19 | Novo Nordisk A/S | Dipeptide comprising a non-proteogenic amino acid |
CN104936610A (en) | 2012-11-13 | 2015-09-23 | 益普生制药股份有限公司 | Purification method of GLP-1 analogue |
WO2014077801A1 (en) | 2012-11-13 | 2014-05-22 | Ipsen Pharma S.A.S. | Purification process for preparing highly pure taspoglutide |
GR20140100479A (en) * | 2014-09-23 | 2016-05-05 | Novetide, Ltd., | Synthesis of liraglutide |
ES2962666T3 (en) | 2018-03-09 | 2024-03-20 | Fresenius Kabi Ipsum S R L | Chemoenzymatic synthesis of liraglutide, semaglutide and GLP-1 |
CN111757891A (en) | 2018-03-09 | 2020-10-09 | 恩细贝普有限公司 | Chemical-enzymatic synthesis of somaglutide, liraglutide and GLP-1 |
EP3864032B1 (en) | 2018-10-09 | 2022-11-30 | Fresenius Kabi iPSUM S.r.l. | Process for the manufacture of glp-1 analogues |
TWI738260B (en) | 2019-03-25 | 2021-09-01 | 台灣神隆股份有限公司 | Process for purifying liraglutide |
EP3753946A1 (en) | 2019-06-18 | 2020-12-23 | Fresenius Kabi iPSUM S.r.l. | Improved process for the preparation of high purity glucagon |
CN114401981A (en) * | 2019-06-18 | 2022-04-26 | 北京费森尤斯卡比医药有限公司 | Process for producing glucagon |
US20230406900A1 (en) * | 2022-06-01 | 2023-12-21 | Scinopharm Taiwan, Ltd. | Process for preparing glucagon-like peptide-1 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6281335B1 (en) * | 1993-10-08 | 2001-08-28 | Coulter Corporation | Hybridoma and anti-KC-4 humanized monoclonal antibody |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
AU5441096A (en) * | 1995-04-14 | 1996-10-30 | The Administrators Of The Tulane Eductional Fund | Analogs of growth hormone-releasing factor |
UA65549C2 (en) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
US6281331B1 (en) * | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
NZ527241A (en) * | 1998-12-07 | 2004-12-24 | Sod Conseils Rech Applic | Analogues of GLP-1 |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US7238671B2 (en) | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
EP1701970A2 (en) * | 2003-12-31 | 2006-09-20 | F.Hoffmann-La Roche Ag | Methods for recovering cleaved peptide from a support |
-
2007
- 2007-06-19 DK DK07765481.2T patent/DK2035451T3/en active
- 2007-06-19 WO PCT/EP2007/056052 patent/WO2007147816A1/en active Application Filing
- 2007-06-19 CA CA2654610A patent/CA2654610C/en not_active Expired - Fee Related
- 2007-06-19 SI SI200730229T patent/SI2035451T1/en unknown
- 2007-06-19 BR BRPI0713575-0A patent/BRPI0713575A2/en not_active IP Right Cessation
- 2007-06-19 JP JP2009515856A patent/JP4537495B2/en not_active Expired - Fee Related
- 2007-06-19 PL PL07765481T patent/PL2035451T3/en unknown
- 2007-06-19 UA UAA200900414A patent/UA96602C2/en unknown
- 2007-06-19 NZ NZ573093A patent/NZ573093A/en not_active IP Right Cessation
- 2007-06-19 DE DE602007006310T patent/DE602007006310D1/de active Active
- 2007-06-19 PT PT07765481T patent/PT2035451E/en unknown
- 2007-06-19 AU AU2007263043A patent/AU2007263043B2/en not_active Ceased
- 2007-06-19 MY MYPI20085211A patent/MY144608A/en unknown
- 2007-06-19 EP EP07765481A patent/EP2035451B1/en active Active
- 2007-06-19 AT AT07765481T patent/ATE466881T1/en active
- 2007-06-19 RU RU2009101969/04A patent/RU2448978C2/en not_active IP Right Cessation
- 2007-06-19 CN CN200780023265.1A patent/CN101563364B/en not_active Expired - Fee Related
- 2007-06-19 KR KR1020087031096A patent/KR101087859B1/en not_active IP Right Cessation
- 2007-06-19 MX MX2008015935A patent/MX2008015935A/en active IP Right Grant
- 2007-06-19 RS RSP-2010/0267A patent/RS51281B/en unknown
- 2007-06-19 ES ES07765481T patent/ES2341588T3/en active Active
- 2007-06-21 AR ARP070102735A patent/AR061604A1/en not_active Application Discontinuation
- 2007-06-21 US US11/821,017 patent/US20080004429A1/en not_active Abandoned
- 2007-06-22 CL CL200701835A patent/CL2007001835A1/en unknown
- 2007-06-22 TW TW096122579A patent/TWI331155B/en not_active IP Right Cessation
-
2008
- 2008-11-19 NO NO20084863A patent/NO20084863L/en not_active Application Discontinuation
- 2008-11-20 IL IL195421A patent/IL195421A0/en unknown
- 2008-11-26 ZA ZA200810072A patent/ZA200810072B/en unknown
- 2008-11-26 CR CR10463A patent/CR10463A/en not_active Application Discontinuation
- 2008-12-22 EC EC2008008999A patent/ECSP088999A/en unknown
- 2008-12-25 MA MA31510A patent/MA30530B1/en unknown
-
2010
- 2010-05-27 HR HR20100302T patent/HRP20100302T1/en unknown
- 2010-06-11 CY CY20101100519T patent/CY1110186T1/en unknown
-
2011
- 2011-05-11 US US13/105,435 patent/US20110213082A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR061604A1 (en) | SYNTHESIS OF AN INSULINOTROPIC PEPTIDE | |
AR069608A1 (en) | METHOD FOR OBTAINING INSULINOTROPIC PEPTIDES USING A COMBINATION OF SOLID PHASE AND SOLUTION TECHNIQUES | |
PA8830501A1 (en) | GLUCAGON / GLP-1 RECEIVER CO-AGONISTS | |
PE20090726A1 (en) | APOPTOTIC ANTI-IGE ANTIBODIES | |
CL2011003121A1 (en) | Fusion protein comprising a growth hormone (gh) sequence, linked to an extended recombinant polypeptide (xten) comprising at least 200 amino acids, lacks t cell epitopes and residues g, a, s, t, e and p add up to more 90%; nucleic acid, vector and cell; Method of production; pharmaceutical composition and use. | |
PE20181322A1 (en) | ANTI-PD1 ANTIBODY AND ITS METHODS OF USE | |
NZ593833A (en) | Extended recombinant polypeptides and compositions comprising same | |
NO20092247L (en) | Boc and Fmoc solid phase peptide synthesis | |
MX2010004297A (en) | Glucagon antagonists. | |
PE20120543A1 (en) | ANTI-TAU ANTI-BODY PS422 | |
AR061097A1 (en) | PROCEDURE FOR SYNTHESIZING THYLOSINS | |
AR062575A1 (en) | METHOD FOR THE PRODUCTION OF CONJUGATES OF THE SIMILAR GROWTH FACTOR TO INSULIN -1 AND POLYETHYLENE GLYCOL | |
AR076977A1 (en) | SELF-ASSEMBLED REPETITIVE PRECURSOR PROTEINS | |
ATE458000T1 (en) | TARGETED FUSION PROTEINS FOR CANCER THERAPY | |
RU2013118446A (en) | METHOD FOR PRODUCING DEGARELIX AND ITS INTERMEDIATE COMPOUNDS | |
PE20090683A1 (en) | SIGNALING PEPTIDES | |
DK2007885T3 (en) | Method for enhancing the in vivo recovery of therapeutic polypeptides | |
ES2531402T3 (en) | Fusion collagenase to which an affinity label binds, and method of producing it | |
MX2007013400A (en) | Solid phase bound thymosin alpha-1 and its synthesis. | |
EA201170477A1 (en) | METHOD OF SYNTHESIS (Aib) hGLP-1 (7-36) -NH | |
DK1953172T3 (en) | TRUNCATED GLUCAGON SIMILAR PEPTID-1 (sGLP-1) AND ITS METHOD AND APPLICATION | |
ATE549346T1 (en) | CHEMICAL MODIFICATION OF PROTEINS | |
DK1704234T3 (en) | Preparation of glucagon-like peptide 2 and analogues | |
TH107349A (en) | Insulinotropic peptide synthesis | |
IL199752A0 (en) | Purification of taci-fc |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |